hTERT C250T promoter mutation and telomere length as a molecular markers of cancer progression in patients with head and neck cancer

Barczak,Wojciech; Suchorska,Wiktoria M.; Sobecka,Agnieszka; Bednarowicz,Karolina; Machczynski,Piotr; Golusinski,Pawel; Rubis,Blazej; Masternak,Michal M.; Golusinski,Wojciech

doi:10.3892/mmr.2017.6590

hTERT C250T promoter mutation and telomere length as a molecular markers of cancer progression in patients with head and neck cancer

Authors:
- Wojciech Barczak
- Wiktoria M. Suchorska
- Agnieszka Sobecka
- Karolina Bednarowicz
- Piotr Machczynski
- Pawel Golusinski
- Blazej Rubis
- Michal M. Masternak
- Wojciech Golusinski
View Affiliations

Affiliations: Department of Head and Neck Surgery, Poznan University of Medical Sciences, The Greater Poland Cancer Centre, Garbary, Poznan, Greater Poland Voivodeship 61‑866, Poland, Radiobiology Lab, The Greater Poland Cancer Centre, Garbary, Poznan, Greater Poland Voivodeship 61‑866, Poland, Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Przybyszewskiego, Poznan, Greater Poland Voivodeship 60‑355, Poland
Published online on: May 17, 2017 https://doi.org/10.3892/mmr.2017.6590
Pages: 441-446

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Squamous cell carcinoma of the head and neck (HNSCC) is the sixth leading cause of cancer worldwide, representing over half a million incidents every year. Cancer cells, including HNSCC, are characterized by increased telomerase activity. This enzymatic complex is active in ~90% of all cancer types and is responsible for the lengthening of telomeres. Highly recurrent point mutations in the human telomerase reverse transcriptase (hTERT) promoter have recently been reported in a number of human neoplasms. The aim of the present study was to analyze the prevalence of the hTERT promoter C250T mutation and telomere length in the blood leukocytes of 61 patients with HNSCC and 49 healthy individuals. Quantitative polymerase chain reaction identified the hTERT promoter mutation in 36% of patients with HNSCC. To the best of our knowledge this is first report indicating the presence of shorter telomeres in early stage tumors. In addition, the results suggest that the C250T hTERT promoter mutation and telomere length assessment may serve as important molecular markers of HNSCC progression.

View Figures

View References

1	Thomas SM and Grandis JR: The current state of head and neck cancer gene therapy. Hum Gene Ther. 20:1565–1575. 2009. View Article : Google Scholar : PubMed/NCBI
2	Suh Y, Amelio I, Guerrero Urbano T and Tavassoli M: Clinical update on cancer: Molecular oncology of head and neck cancer. Cell Death Dis. 5:e10182014. View Article : Google Scholar : PubMed/NCBI
3	Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, et al: Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 99:777–789. 2007. View Article : Google Scholar : PubMed/NCBI
4	Szeszko B, Osowiecka K, Rucińska M, Wasilewska-Teśluk E, Gliński K and Kepka L: Smoking during radiotherapy for head and neck cancer and acute mucosal reaction. Rep Pract Oncol Radiother. 20:299–304. 2015. View Article : Google Scholar : PubMed/NCBI
5	Vojtíšek R, Ferda J and Fínek J: Effectiveness of PET/CT with (18)F-fluorothymidine in the staging of patients with squamous cell head and neck carcinomas before radiotherapy. Rep Pract Oncol Radiother. 20:210–216. 2015. View Article : Google Scholar : PubMed/NCBI
6	Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, et al: Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 18:541–550. 2009. View Article : Google Scholar : PubMed/NCBI
7	Chen CH and Chen RJ: Prevalence of telomerase activity in human cancer. J Formos Med Assoc. 110:275–289. 2011. View Article : Google Scholar : PubMed/NCBI
8	McEachern MJ, Krauskopf A and Blackburn EH: Telomeres and their control. Annu Rev Genet. 34:331–358. 2000. View Article : Google Scholar : PubMed/NCBI
9	Hug N and Lingner J: Telomere length homeostasis. Chromosoma. 115:413–425. 2006. View Article : Google Scholar : PubMed/NCBI
10	Bibby MC: An introduction to telomeres and telomerase. Mol Biotechnol. 24:295–301. 2003. View Article : Google Scholar : PubMed/NCBI
11	Suchorska WM, Augustyniak E and Łukjanow M: Genetic stability of pluripotent stem cells during anti-cancer therapies. Exp Ther Med. 11:695–702. 2016.PubMed/NCBI
12	Chan S and Blackburn EH: Telomeres and telomerase. Philos Trans R Soc Lond B Biol Sci. 359:109–121. 2004. View Article : Google Scholar : PubMed/NCBI
13	Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013. View Article : Google Scholar : PubMed/NCBI
14	Jangard M, Zebary A, Ragnarsson-Olding B and Hansson J: TERT promoter mutations in sinonasal malignant melanoma: A study of 49 cases. Melanoma Res. 25:185–188. 2015. View Article : Google Scholar : PubMed/NCBI
15	Khan S, Shukla S, Sinha S and Meeran SM: Role of adipokines and cytokines in obesity-associated breast cancer: Therapeutic targets. Cytokine Growth Factor Rev. 24:503–513. 2013. View Article : Google Scholar : PubMed/NCBI
16	Barczak W, Rozwadowska N, Romaniuk A, Lipińska N, Lisiak N, Grodecka-Gazdecka S, Książek K and Rubiś B: Telomere length assessment in leukocytes presents potential diagnostic value in patients with breast cancer patients. Oncol Lett. 11:2305–2309. 2016.PubMed/NCBI
17	Cawthon RM: Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res. 37:e212009. View Article : Google Scholar : PubMed/NCBI
18	Gruszecka A, Kopczyński P, Cudziło D, Lipińska N, Romaniuk A, Barczak W, Rozwadowska N, Totoń E and Rubiś B: Telomere shortening in down syndrome patients-when does it start? DNA Cell Biol. 34:412–417. 2015. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Sturgis EM, Dahlstrom KR, Wen J, Liu H, Wei Q, Li G and Liu Z: Telomere length in peripheral blood lymphocytes contributes to the development of HPV-associated oropharyngeal carcinoma. Cancer Res. 73:5996–6003. 2013. View Article : Google Scholar : PubMed/NCBI
21	Bau DT, Lippman SM, Xu E, Gong Y, Lee JJ, Wu X and Gu J: Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. Cancer. 119:4277–4283. 2013. View Article : Google Scholar : PubMed/NCBI
22	Liu Z, Ma H, Wei S, Li G, Sturgis EM and Wei Q: Telomere length and TERT functional polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 20:2642–2645. 2011. View Article : Google Scholar : PubMed/NCBI
23	Oh BK, Kim H, Park YN, Yoo JE, Choi J, Kim KS, Lee JJ and Park C: High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab Invest. 88:144–152. 2008. View Article : Google Scholar : PubMed/NCBI
24	Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al: Frequency of TERT promoter mutations in human cancers. Nat Commun. 4:21852013. View Article : Google Scholar : PubMed/NCBI
25	Vinothkumar V, Arunkumar G, Revathidevi S, Arun K, Manikandan M, Rao AK, Rajkumar KS, Ajay C, Rajaraman R, Ramani R, et al: TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. Tumour Biol. 37:7907–7913. 2016. View Article : Google Scholar : PubMed/NCBI
26	Qu Y, Dang S, Wu K, Shao Y, Yang Q, Ji M, Shi B and Hou P: TERT promoter mutations predict worse survival in laryngeal cancer patients. Int J Cancer. 135:1008–1010. 2014. View Article : Google Scholar : PubMed/NCBI
27	Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, et al: TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 99:E1130–E1136. 2014. View Article : Google Scholar : PubMed/NCBI
28	George JR, Henderson YC, Williams MD, Roberts DB, Hei H, Lai SY and Clayman GL: Association of TERT promoter mutation, but not braf mutation, with increased mortality in PTC. J Clin Endocrinol Metab. 100:E1550–E1159. 2015. View Article : Google Scholar : PubMed/NCBI
29	Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 20:603–610. 2013. View Article : Google Scholar : PubMed/NCBI